FOSUN PHARMA
复星医药

Investor Presentation

3Q22 Report

Prepared in accordance with China Accounting Standards

Contents

1 Financial Results

2 Strengths

3 Pharmaceutical

4 Med Tech

5 Healthcare Services

Financial Results

Financial Results Overview

Key Financials (RMB million)	3Q21	3Q22	YoY(%)
Revenue	27,048	31,610	16.87
Net profit attributable to shareholders	3,565	2,454	-31.15*
Net profit after one-off gain	2,475	2,859	15.51*
Net operating cash flow	3,016	3,173	5.24
R&D Expenditure	3,151	3,761	19.36
R&D Expense	2,414	2,849	18.02
Basic EPS (RMB/Share)	1.39	0.95	-31.65*

Note: realized net profit after one-off gain RMB2,859 million (+15.51% YoY) in 3Q22; sustainable revenue and net profit after one-off gain growth; the decrease of net profit attributable to shareholders and basic EPS was mainly due to the decrease in one-off gain, BNTX share price decreased because of market fluctuations and other factors. The change in fair value of financial assets results a one-off loss over RMB1.1 billion for the reporting period

Segment Revenue



Financail Results Overview – By Quarter

Revenue



Operating Cash Flow



Proft Attributable



Net Profit after One-off Gain



Operating Performance Analysis

Expense Structure	2021	3Q21	3Q22
Gross Margin[1]	*48.1%*	*49.6%*	*46.5%*
Selling and Distribution[2]	*23.3%*	*24.2%*	*20.5%*
Administrative	*8.2%*	*8.3%*	*8.3%*
R&D	*9.8%*	*8.9%*	*9.0%*
Finance	*1.2%*	*1.5%*	*1.2%*
Gross Margin minus Selling and Distribution[3]	*24.8%*	*25.3%*	*26.0%*

Note: Operating cost and selling and distribution expenses for 3Q21 have been restated due to adjustments in the transportation cost

Note[1]: The decrease of Gross Margin in 1H22 was mainly due to:1) the unit price increase of some core products due to the increase in labor costs and raw materials under the pandemic; 2) the lower gross margins on not self-developed Covid-19 products; 3) impact of volume based purchasing

Note[2]: The decrease of Selling and distribution rate was mainly due to:1) continuously strengthen the control of sales expanse; 2) the decreased selling and distribution rate of volume-based purchasing products

Note[3]: Gross Margin minus Selling and Distribution remained consistent

(RMB million)

Operating Results



Operating Results Margins	1H21	1H22
Total Results Margin	*10.3%*	*9.2%*
Pharmaceutical	*11.0%*	*13.2%*
Med Tech	*15.3%*	*10.9%*
Healthcare Services	*-1.1%*	*-13.3%*

Note: segment result increased 52.25% YoY, excluding the impact from equity transfer of Yaneng Bioscience,

Business Highlights - The “4IN” Strategy

Fosun Pharma maintained solid revenue and operating performance growth in 1H22 from increased sales volume of products launched in last 3 years, sales in Covid-19 related products and effective control of marketing expenses

INnovation

Improving Product Portfolio

- **Serplulimab Injection (PD-1) for MSI-H was approved in China;** sqNSCLC, EC-SCLC and ESCC indications were accepted by the NMPA. SCLC was granted FDA Orphan-drug Designation
- Yi Kai Da LBCL second-line therapy was accepted by NMPA and granted with Priority Review in October 2022.
- Entered into a strategic collaboration with Genuine Biotech to develop and exclusively commercialize **Azvudine,** the first domestic small molecule anti Covid-19 oral drugs. **Azvudine** has been commercialized in Chinese mainland.
- Approved mRNA Covid-19 vaccine versions for children aged 5-11 and for infant aged 6 months to 4 years old EUA in Hong Kong in Sep. 2022 and approved Omicron BA.4/BA.5-adapted bivalent vaccine for 12 years of age and older EUA in Taiwan region in Oct. 2022
- **BD:** license-in products include Keverprazan Hydrochloride and Grafalon

INternationalization

Enhancing Global Operating

- Entered into the collaboration and license agreement with Amgen for the exclusive right to commercialize Otezla® and Parsabiv® in Chinese Mainland, another collaboration case with reputable MNC
- Henlius entered into the license agreement with companies including Organon, Eurofarma and Getz Pharma to cover the main biologics market including the U.S., EU and other emerging markets with international partners
- Sublicensed from MPP to **manufacture** both drug substance and product and commercialize COVID-19 oral drugs **Molnupiravir and Paxlovid** in agreed low- and middle-income countries
- Building the 2nd headquarter in the U.S.; has 5 regional distribution hubs in Africa; the largest distribution hub in French-speaking West Africa, the Côte d'Ivoire distribution hub has been put into operation

INtegration

Accelerating strategic upgrade and internal integration

- **Pharma Segment:** Subdivided into three divisions Innovative Medicines Divisions, Established Medicines Manufacturing &Supply Division, and Vaccines Division in early 2022.
- **Med Tech:** Sisram strengthened global direct sales teams and the proportion of direct sales revenue continues to increase. Integrating of Medical Diagnosis Segment to improve the R&D and manufacturing capabilities of diagnostic instruments

INtelligentization

Intelligent Operation Driven by Digital Transformation

- Upgrading the R&D digital platform INNOX2.0 for collaborative innovation to improve the efficiency of R&D project management and explore AI-driven R&D
- Providing integrated online and offline healthcare services to become the leader of family active health

Other Progress: 1) Fosun Pharma’s MSCI ESG rating has been upgraded from BB in 2020 to BBB in 2021 and to A in October 2022, leading the domestic industry; **2)** announced to collaborate with CR Pharmaceutical on strategic and business level of innovative medicines, biologics, medical devices, etc.

Strengths

Fosun Pharma - Forward-looking Industry Insights

Industrial investment empowers innovation and globalization, quick response to challenges and access to cutting-edge fields and technologies

Risk Identification

Identified the Irrationality of High Profit Generic Drugs
Prepared quality consistency evaluation before “4+7” drug procurement; accelerating manufacturing integration to improve the competitiveness

Strategy Implementation

Forward-looking Globalization
Entered into the global market before domestic competitors via industrial investment as domestic market become increasingly competitive

Clinical Value-oriented Innovation Since 2009
Building small molecule innovative drugs, antibody drugs, cell therapy platforms etc.

Industrial Investment & Quick Response

Innovative Technology
- Launched the first CAR-T cell therapy product in China, Yi Kai Da.
- Collaborated with BioNTech on mRNA technology
- Collaborated with Insilico to enter AI-driven drug discovery and development

Biopharmaceuticals
- Launched China’s first biosimilar product Han Li Kang
- Launched the first mAb product Han Qu You approved in both China and EU
- Han Si Zhuang was granted Orphan-drug Designation by FDA in treating SCLC

Seize the Opportunities

Innovative Medical Devices
- Acquired Alma to enter energy-based aesthetic medical devices business and to establish Wellness Ecosystem
- Found Intuitive Fosun with Intuitive Surgical as the representative of da Vinci robotic-assisted surgical system in China

Quick Response against COVID-19
- Quick response against COVID-19 by covering products and services in prevention, test and treatment of COVID-19

Differentiated Innovation - from R&D to Market

- Rituximab Injection
- Trastuzumab Injection
- Serplulimab Injection
- FCN-338（BCL-2）
- FCN-159 （MEK）
- ORIN-1001

- Azvudine
- Avatrombopag Tablets
- Opicapone
- RT002
- Tenapanor Tablets
- SurVaxM
- FS-1502

- mRNA Covid-19 Vaccine
- Axicabtagene Ciloleucel
- da Vinci Surgical System

BIONTECH Kite INTUITIVE SURGICAL

- Gene Therapy
- Oncolytic Virus
- Individualized Vaccine for Cancer Treatment(AC-NP)/Multispecific Immunonano Therapy(MINP)
- Lung Cancer Early Diagnosis and treatment (Jedicare)

In-house R&D

In-license

Co-development

Incubation & Early Stage Investments

Diversified R&D System

Strengthen middle office capabilities including project approval, clinical, registration, etc.

Commercialization team with over 6,900 employees to maximize product value

Globalization - Maximize Product Value

Revenue from regions outside Chinese Mainland and other countries

1H22 Revenue

RMB 7,592 million

RMB5,198 million in 1H21

% Total Revenue

35.58%

30.66% in 1H21

1H22 Main Progress

The U.S.

- Collaborated with **5** major wholesalers, **16** GPOs, **21** distributors in the U.S. market. **19** collaboration contracts covered 85% of the IDNs
- **Sisram's** North American direct sales revenue was **USD69.9 million (+42.2% YoY)**, **40%** of the total revenue

Africa

- **Côte d'Ivoire Pharmaceutical distribution hub** in West Africa has been put into operation; **Kenya distribution hub** passed the ICRC on-site inspection

**2022 Q3 did non disclose globalization separately*

Global Presence

- European subsidiary established in 2017 based on various collaborations, to **capture the value of innovative medicines**
- Launched the **first** domestic biosimilar in EU
- Covering early stage incubation, BD, preclinical and clinical research and other innovative R&D

Past

Now & future



- Acquired the **third largest** pharma distributor in French-speaking West Africa, **Tridem Pharma**, in 2017
- Integrated public markter team in Guilin Pharma with private market team inTridem Pharma
- Established **5 regional distribution hubs** with about **800** people in the commercialization team
- Strengthening marketing and **local manufacturing** capabilities

- Acquired the **first** FDA approved injectables manufacturer in India, **Gland Pharma**, in 2017
- Focusing on **complex injectables** and expanding to **biologics CDMO**
- Accelerating product registration in China

- Entered into the U.S. market by exporting formulations and other businesses. Established **the U.S. subsidiary** in 2017. Has Hengenix Biotech, Fusion and other platforms in the U.S.
- Building **the 2nd headquarter** in the U.S. to improve operation
- Have direct sales team for generic drugs and medical devices
- **Strengthening BD capability of clinical stage products and commercialization capability of innovative medicines**

Figure number: GS(2016)1666

6,099 overseas employees, 16.7% of the total number of employees

Completed the first stage of globalization

Accelerating the overseas commercialization of competitive products

Trustworthy Partner of MNCs

- **Diversified R&D System**
- **Forward-looking Globalization**
- **Global network with overseas subsidiaries and VC funds**
- **>20yrs domestic industrial experiences with complete clinical registration and commercialization system as well as financial, legal and other capabilities**
- **Trustworthy partner with numerous collaborations**

Quick access to cutting-edge fields and technologies through collaboration
Reached dozens of international collaborations with well-known MNCs

INTUITIVE SURGICAL®

- Entered into a distribution partnership with Intuitive Surgical through subsidiary Chindex Medical, brought da Vinci Surgical System to China
- Announced to found JV Intuitive Fosun with Intuitive Surgical in September 2016 to further collaborate in technology, manufacturing and services

Kite, A GILEAD Company

- Founded JV Fosun Kite with Kite Pharma in 2017 to build the leading cell therapy platform in China
- Yi Kai Da is the first CAR-T therapy approved in China. FKC889 for MCL is in the clinical stage in China

BIONTECH

- Collaborated with BioNTech to develop and commercialize mRNA Covid-19 vaccine in China in March 2020
- Sales over 30 million doses in Hong Kong, Macau and Taiwan region by the end of June 2022

AMGEN®

- Entered into the collaboration and license agreement with Amgen for the exclusive right to commercialize Otezla® and Parsabiv® in Chinese Mainland to strengthen non-oncology product pipeline
- Commercialization capability recognized by MNC, exploring new collaboration in innovative medicines

Quick Response - Product Portfolio Against COVID-19

Covid-19 Antiviral Treatment

Azvudine

- Entered into a strategic collaboration with Genuine Biotech to develop and exclusively commercialize Azvudine, the first domestic small molecule anti Covid-19 oral drugs
- Obtained emergency conditional approval from NMPA to treat adult patients suffering moderate Covid-19 on July 25th
- Included in the Covid-19 prevention and control protocol (9th edition); included in the medical insurance in 31 provinces, autonomous regions and municipalities; passed the format review of 2022 NRDL adjustment; priced at RMB270 for a course of treatment
- Collaborated with Sinopharm to supply Azvudine in Chinese Mainland. Azvudine has been delivered to Xinjiang, Hainan, Henan, Yunnan, Inner Mongolia, etc. to fight against Covid-19 pandemic

Sublicensed from MPP

- Sublicensed from MPP to manufacture drug substance and drug Molnupiravir from MSD and to commercialize in 105 low-and middle-income countries
- Sublicensed from MPP to manufacture drug substance and drug Nirmatrelvir from Pfizer and to commercialize drug substance and Paxlovid from Pfizer (Nirmatrelvir tablets and Ritonavir tablets) in 95 low-and-middle income countries

Others

- Entered into a license agreement with Kintor Pharma to commercialize Proxalutamide in India and 28 African countries
- Product pipeline includes long-acting fusion protein drugs and bispecific nano-antibodies

Covid-19 Diagnostic Test Kit & Biomedlab

Covid-19 nucleic acid test kit

Received certifications from NMPA, CE, FDA, EUA, WHO EUL, TGA, etc., suppling to more than 10 countries and regions worldwide

COVID 19 antigen test kit

Received certification from NMPA, CE; completed the German BfArM registration; included in the EU COVID 19 Rapid Antigen Tests Common List; received FDA Emergency Use Authorization

Covid-19 Vaccine

mRNA Covid-19 Vaccine

- Included in the Covid-19 vaccination programmes in Hong Kong and Macau region in March 2021 and started vaccine administration in Taiwan region in September 2021. Vaccine sales over 30 million doses in Hong Kong, Macau and Taiwan region since launched.
- Continuously expanding the eligibility of vaccine for babies and children under 12 yrs old and the eligibility of bivalent vaccine booster in 2022. Approved vaccine administration for 6 mths-4 yrs old in August and for 5-11 yrs old in May in Taiwan region; approved vaccine versions for 6 mths-4 yrs old and 5-11 yrs old EUA in Hong Kong in September; received vaccine special import authorization for 6 mths-4yrs old in October and approved vaccine for 5-11 yrs old in April in Macau
- Authorized Omicron BA.4/BA.5-adapted bivalent vaccine EUA in Taiwan region in October; submitted applications of Omicron BA.4/BA.5-adapted bivalent vaccine in Hong Kong (EUA) and Macau (special import authorization)

Environmental, Social and Governance

MSCI-ESG Rating Upgrade



- Upgraded **MSCI ESG rating to A** in October 2022, leading the industry
- Topped in the first **Fortune China ESG Impact List** in August 2022
- Included in the **HSCASUS and HSMHSUS**

E nvironment

Green growth and sustainable development

- Established EHS Committee to continuously improve EHS policies and set the 2nd EHS five-year strategic goals (2021-2026)
- Implemented sustainable supply chain, improved production efficiency and developed a preliminary climate change risk list

S ocial

Improvement of product accessibility and affordability, taken the interest of stakeholders into consideration

- Well-established systems and organizations for R&D, product quality management, staff training, social welfare and supply chain management
- Organized or participated in anti-malaria activities in Africa, medicine donation programs, rural doctors activities, poverty alleviation fund, Fosun Health Management Institute, etc.

G overnance

Strengthen corporate governance with ESG to achieve sustainable development

- Established ESG Committee at the Board level; the Anti-Corruption Supervision Department (ACSD) designed a comprehensive anti-corruption system
- Upheld the professional, branded, digital and compliant marketing system control

Pharmaceutical

Pharma Segment Performance

Segment Revenue

(RMB million)



Segment Results

(RMB million)



Segment Profit[1]

(RMB million)



Pharma

3 Divisions | **Specialization**

- **Innovative Medicines**
- **Established Medicines Manufacturing & Supply**
- **Vaccine**

Note1: Segment profit excludes fair value changes of BNTX shares and gain on sale of certain shares

Pharma Segment Core Therapeutic Area Revenue



- **Anti-tumor and immune modulation core products:** increase was mainly due to the revenue increase from Han Qu You (Trastuzumab Injection), Han Li Kang (Rituximab Injection), and Su Ke Xin (Avatrombopagmaleate Tablets) and the revenue from new launches including Han Si Zhuang (Serplulimab Injection) and Akynzeo (Netupitant-Palonosetron)
- **Anti-infection core products:** increase was mainly due to the sales contribution from mRNA COVID-19 vaccine and the sales revenue increase of anti-malarial products (Artesunate)
- **Metabolism and alimentary system core products:** decrease was mainly due to the decrease in sales volume and unit price of Atomolan (glutathione for injection) and Fan Ke Jia (thioctic acid injection) after the volume-based purchasing
- **Cardiovascular system core products:** increase was mainly due to the revenue increase from heparin series preparations
- **Central nervous system core products:** decrease was mainly due to the sales decline of Ao De Jin (DeproteinizedCalf Blood Injection)

Note: 1H21 revenue is restated by including new core product Wan Su Jing (Engeletin Tablets) and excluding Shi Li Da (amlodipine besylate tablets) from disposed Huanghe Pharma in 1H22

Pharma Segment Revenue Structure Optimization

Revenue Structure Changed as Product Portfolio Optimization

Past

Ao De Jin
You Di Er
You Li Tong
Bang Ting
Yan Hu Ning


Now

Future

Revenue mainly contributed by:

- **mRNA COVID-19 vaccine:** help to against COVID-19 in Hong Kong, Macau and Taiwan
- **Han Li Kang (Rituximab Injection):** the first biosimilar product approved in China
- **Han Qu You (Transtuzumab Injection):** the first mAb product approved in both China and the EU
- **Su Ke Xin (Avatrombopag Tablets)**: the first oral drug approved to treat low blood platelet count in adults with long-lasting (chronic) liver disease (CLD)
- **Artesunate and other anti-malarial product:** have saved more than 48 million lives



Examples of core innovative product pipeline

- Received NMPA approval for the first innovative biological drug Serplulimab MSI-H indication. The NDA for sqNSCLC, ES-SCLC and ESCC was accepted by NMPA
- Yi Kai Da (Axicabtagene Ciloleucel Injection) became the first CAR-T cell therapy product approved for launch in China in June 2021
- long-lasting DaxibotulinumtoxinA product RT002, Bcl-2 inhibitor, ORIN1001, MEK1/2 inhibitor, FCN-159 ⋯ ⋯

Pharma Segment Growth Driver

Growth Driver

% of 1H22 revenue from products launched in the last three years over

25%

Han Qu You (Trastuzumab injection)

1H22 Sales

RMB813 million

+150.15% YoY

Increased 24,000L commercial production capacity

Su Ke Xin (Avatrombopag Tablets)

1H22 Sales

RMB360 million

Han Si Zhuang (Serplulimab Injection)

Launched for 3 months

Sales **RMB 77 million**

Completed tenders on procurement platforms in **18 provinces**

Treated **2,485** patients

Han Li Kang (Rituximab Injection)

1H22 Sales

RMB819 million

RA indication was approved in February 2022

mRNA COVID-19 vaccine

1H22 sales in Hong Kong, Macau and Taiwan region over

8 million doses

Approved to use in children aged 5 to 11 in April/May in Macau/Taiwan region

Innovative R&D - Expenditure & Major R&D Progress

1H22 R&D Expenditure
RMB2,399 million
1H22 R&D Expense
RMB1,818 million

- Pharma R&D expenditure is RMB2,062 million, **14.39%** of Pharma revenue. Pharma expense is RMB1,491 million, **10.41%** of Pharma revenue
- Strong R&D capabilities with **260** ongoing pipeline projects by the end of 2021 (not including Gland Pharma's pipeline)





Major R&D progress

- **Serplulimab injection (PD-1) :**1) MSI-H was approved by NMPA in March 2022; 2) the NDA of PD-1 in combination with chemotherapy in treating sqNSCLC was accepted by NMPA in September 2021; 3) the NDA of PD-1 in combination with chemotherapy in treating ES-SCLC was accepted by NMPA and SCLC was granted FDA Orphan-drug Designation in April 2022; 4) the NDA of PD-1 in combination with chemotherapy in treating ECSS was accepted by NMPA in August 2022
- **FS-1502 (Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection Monomethyl Auristatin F):** initiated Phase 2 clinical trial in Chinese Mainland in treating NSCLC; 2) approved to enter Phase 2 clinical trial in combination with Serplulimab and/or chemotherapy in treating advanced gastric cancer with HER2 expression in Chinese Mainland
- **FCN-159 (MEK1/2 inhibitor):** 1) approved to enter Phase 2 clinical trial in Chinese Mainland in treating histiocytic tumor and arteriovenous malformation;2) ongoing Phase 2 global multi-center clinical trial in treating Neurofibromatosis type 1
- **Progress in 1H22:** launched **2** innovative medicine/new indication (Serplulimab MSI-H indication, Rituximab RA indication); launched in total **10** generic drug/indication in Chinese Mainland and the U.S.; **1** innovative medicine/indication and 18 generic drug/indication NDA in Chinese Mainland;**14** innovative medicine/indication and 9 generic drug/indication IND in Chinese Mainland

Innovative R&D - In-house R&D

Enhance in-house R&D capabilities

Henlius

Pipeline covers **oncology, autoimmune areas etc.**; launched China's first biosimilar product Han Li Kang, and the first mAb product Han Qu You approved in both China and EU

Fochon

Pipeline candidates FCN-437 in Phase 3 clinical trial; FCN-159 (MEK1/2) clinical trial in China, U.S. and Europe; the right outside of Chinese Mainland, Hong Kong and Macau of FCN-338 (BCL-2) was granted to Lilly

Fosun Orinnove

First-in-Class R&D strategy. Pipeline candidate Orin1001 is with novel target, MOA and compound

Novelstar

R&D of **special formulation** for multiple DDSs including transdermal, inhalation, slow-release and controlled-release

- **Gene Therapy Platform**
- **Nanobody and Bispecific Antibody Platform**
- **Oncolytic Virus Platform**
- **Personalized Therapeutic Tumor Vaccine (AC-NP) & Multi-specific Immuno-nano Therapy (MINP)**
- **siRNA Therapy Platform**
- **mRNA Platform**
- **Cell Therapy Platform**
- **Fusion Protein Platform**

Figure number: GS(2016)1666

Innovative R&D - License- In & Out

Maximize product value

2022 License In Cases

Furmonertinib
Granted with exclusive right to commercialize in broad region

Otezla® & Parsabiv®
Granted with exclusive right to commercialize 2 innovative medicines in Chinese Mainland

Bifunctional Sialidase Therapies
Co-develop with Nobel Price laureate co-founded Palleon; received exclusive license in China (including Hong Kong, Macau, and Taiwan region)

Azvudine
Entered into the strategic collaboration with GENUINE regarding Azvudine, the first domestic oral small molecule drug for COVID-19 treatment approved in China

Keverprazan Hydrochloride
Granted with exclusive right to commercialize in Chinese Mainland and granted with exclusive rights in other regions or counties as the marketing authorization holder

Maximize Product Value

2022/4 → 2022/5 → 2022/6 → 2022/7 → 2022/9

2022 License Out Cases

Rituximab, Trastuzumab and Bevacizumab
Granted Eurofarma to develop, manufacture and commercialize Rituximab, Trastuzumab and Bevacizumab in 16 Latin American countries; Eurofarma shall pay up to USD50.5 million

Rituximab & Trastuzumab
Granted Abbott semi-exclusive license to commercialize Rituximab and Trastuzumab in Brazil; Abbott shall pay up to USD4.4 million

Pertuzumab & Denosumab
Granted Organon exclusive right to commercialize Pertuzumab and Denosumab in ex-China countries and regions. Organon shall pay up to USD541 million

Innovative R&D - Co-development

Co-development cases: Deepen international collaboration, accessing cutting edge technologies

Yi Kai Da (Axicabtagene Ciloleucel Injection) became the first CAR-T cell therapy product approved for launch in China in June 2021

Indication Expansion

~ 90,000 new NHL patients in China each year, **~ 10,000 patients** with third-line treatment*

Significant needs potential as moving from third-line treatment to second-line treatment

- **LBCL third-line therapy:**

Yi Kai Da became the first CAR-T cell therapy product approved for launch in China in June 2021

Yescarta launched in the U.S. in October 2017

- **LBCL second-line therapy:**

Yescarta became the world's first CAR-T cell therapy product approved by FDA for LBCL second-line therapy

Yi Kai Da LBCL second-line therapy was accepted by NMPA and granted with Priority Review in October 2022.

Yescarta (ZUMA-1):

5yrs OS **42.6%; for CR patients, 5yrs OS 64.4%**

Multicenter Clinical Trial in China for Bridging Study:

ORR 79.2%

Yescarta (ZUMA-7):

Yescarta vs. SOC **in second-line therapy of r/r DLBCL** (Median follow-up: 24.9mths)

ORR: 83% vs. 50%; **CR:** 65% vs. 32%

Median EPS: 8.3mths vs. 2mths

Commercialization

- Treated over 200 patients by the end of July 2022 with nearly 100 certified treatment centers and 10,000 m^2 GMP commercial manufacturing facility
- Exploring diversified payment methods, including commercial insurance and citizen insurance. Yi Kai Da is included in over 50 commercial insurances and 44 citizen insurances by the end of July 2022.

Product Pipeline

- The second indication r/r iNHL was granted Breakthrough Therapy Designation by the NMPA in August 2021 and the clinical trials in China are under process
- FDA approved Tecartus (brexucabtagene autoleucel) for the treatment of adult patients with relapsed/refractory mantle cell lymphoma (MCL) in July 2020; FKC889 for MCL is in the clinical stage in China

Note*: source from Global Cancer Statistics 2018

Innovative R&D - Incubation & Early Stage Investments

Incubation & Early Stage Investments: enrich the R&D pipeline to target cutting-edge technologies at an earlier stage

Incubation

Fosun Lead was founded in 2019, focusing on world-leading biotechnologies and information technologies. Including gene therapy platform GeCell, AI-assisting precision medicine for Oncology, personalized new antigen immunotherapy and others . Other projects includes portable MRI, handheld ultrasound device and Protein Sequencer

Fusion is a platform under Fosun Pharma US in Boston and incubated **Archimmune Therapeutics** which has two **immuno-oncology platforms**: personalized cancer vaccine (ACNP) and Multi-specific immuno-nano therapy (MINP)

Early-stage Investment

Participated in **overseas healthcare professional funds** such as Pontifax Venture Capital、Berkeley Catalyst Fund I, LP、Partners Innovation Fund II, LP for access to leading technologies globally with potential in-license and other collaboration opportunities

Fosun Health Capital has completed financing as Fosun's first VC fund for innovative drugs. Project invested so far include **Biomissile (bi-specific antibody)** and **Tianjin JuveStar (medical aesthetic)**

Innovative R&D - Biopharmaceuticals Core Pipeline

Therapeutic Area	Product		Target/MOA	Indication	Pre-Clinical / IND / Phase 1 / Phase 2 / Phase 3 / NDA
Anti-tumor	HLX10[1] (Serplulimab) KGbio	+Chemo	PD-1	Squamous non-small cell lung cancer 1L	Global multi-center clinical trial, NDA accepted by NMPA in September 2021
				Extensive-stage small cell lung cancer 1L	Granted FDA Orphan-drug Designation in April 2022
				Metastatic esophageal squamous-cell carcinoma 1L	
				Limited-stage small cell lung cancer	Global multi-center clinical trial; First subject had been dosed in Chinese Mainland in May 2022;
				Neo-/adjuvant treatment of gastric cancer	
		+Bevacizumab	PD-1+VEGF	Non-squamous non-small cell lung cancer 1L	
				Hepatocellular carcinoma 1L	
				Metastatic colorectal cancer 1L	
		+HLX07	PD-1+EGFR	Squamous-cell carcinoma of the head and neck 2L	
				Squamous non-small cell lung cancer 1L	First subject had been dosed in January 2022
	HLX04-O[2] ESSEX 亿胜		VEGF	Wet age-related macular degeneration	First subject had been dosed in Chinese Mainland Phase 3 clinical trial in November 2021; First subject had been dosed in Latvia Phase 3 clinical trial in April 2022
	HLX22	+Trastuzumab	HER2+HER2	Gastric cancer	Initiated Phase 2 clinical trial in Mainland China in September 2021
	HLX07		EGFR	Solid tumors (non-small cell lung cancer, esophageal carcinoma, etc.)	Approved to enter clinical trials by FDA
	HLX11 (Pertuzumab) [3] ORGANON		HER2	Breast cancer	Initiated Phase 3 clinical trial in Chinese Mainland in April 2022
	HLX05 (Cetuximab) [4] Jingze		EGFR	Metastatic colorectal cancer and squamous-cell carcinoma of the head and neck	
	HLX12 (Ramucirumab)		VEGFR2	Gastric cancer, metastatic non-small cell lung cancer and metastatic colorectal cancer	

Note 1: granted KG Bio to develop and commercialize HLX10 in 10 countries in Southeast Asia
Note 2: granted ESSEX an exclusive license to develop, manufacture, and commercialize HLX04 in human ophthalmic therapeutic use
Note 3: granted Organon exclusive global commercialization rights except for China
Note 4: granted Jingze Biotech to commercialize HLX05 in China
Note 5: last update on 30th October 2022

Innovative R&D - Biopharmaceuticals Core Pipeline

Therapeutic Area	Product	Target/MOA	Indication	Pre-Clinical / IND / Phase 1 / Phase 2 / Phase 3 / NDA
Anti-tumor	FS-1502	HER2	Non-small cell lung cancer	Approved to enter Phase 2 clinical trial by NMPA in May 2022
			HER2-positive advanced malignant solid tumor	
			HER2-positive locally advanced or metastatic breast cancer	
	FS-1502+Serplulimab	HER2+PD-1	Advanced gastric cancer with HER2 expression	Approved to enter clinical trials by NMPA in July 2022
	HLX14 (Denosumab)[1] ORGANON	RANKL	Osteoporosis	Initiated Phase 3 clinical trial in Chinese Mainland in June 2022; approved to enter Phase 3 clinical trial in TGA in July 2022
	HLX26	LAG-3	Solid tumors and lymphomas	Approved to enter clinical trials by NMPA in April 2021
	HLX35[2] BINACEA	EGFR×4-1BB	Solid tumors	Approved to enter clinical trials by NMPA in January 2022; first subject had been dosed in Chinese Mainland in June 2022
	HLX301	PD-L1×TIGIT	Solid tumors	First subject had been dosed in Australia in February 2022; Approved to enter clinical trials by NMPA in March 2022; first subject had been dosed in Chinese Mainland in July 2022
	HLX13 (Ipilimumab)	CTLA-4	Melanoma, renal cell carcinoma and metastatic colorectal cancer	
	HLX15 (Daratumumab)	CD38	Multiple myeloma	
	HLX23	CD73	Solid tumors	
	SurvaxM Injection	Survivin	Malignant glioblastoma	Approved to enter clinical trials by NMPA in March 2022
Blood system	Recombinant Human Erythropoietin Injection (pre-filled syringe)	EPO	Anemia of renal disease	NDA was accepted by NMPA in December 2021
Metabolism and Digestive System	Recombinant Insulin Glargine Injection	INSR	Diabetes	
	Mixed Protamine Zinc Recombinant Insulin Lispro Injection (50R)	INSR	Diabetes	
	Liraglutide Injection	GLP-1	Diabetes, Obesity	
Others	RT002	Bio 1	Moderate to severe glabellar lines in adults (GL)	Completed the enrollment of subjects in Chinese Mainland in September 2021
		Bio 1	Cervical dystonia (CD)	Completed the enrollment of subjects in Chinese Mainland in January 2022
	13-Valent Pneumococcal Conjugate Vaccine	Vaccine	Prevention of Streptococcus pneumonia	Preparing the Phase 3 clinical trial

Note 1: granted Organon exclusive global commercialization rights except for China

Note 2: granted Binacea to research, develop, manufacture and commercialize the HLX35 globally except for China (including Hong Kong, Macau and Taiwan region)

Note 3: last update on 30th October 2022

Innovative R&D - Small Molecule Core Pipeline

Therapeutic Area	Project	Target/MOA	Indication	Pre-Clinical / IND / Phase 1 / Phase 2 / Phase 3 / NDA
Anti-tumor	FCN-437c	CDK4/6	Breast cancer (1L)	Approved to enter Phase 3 clinical trial by NMPA in January 2022; Phase 1 clinical trial in the U.S.
			Breast cancer (2L)	Approved to enter Phase 3 clinical trial by NMPA in January 2022; Phase 1 clinical trial in the U.S.
	SAF-189	ALK	Non-small cell lung cancer	Initiated Phase 3 clinical trial in Mainland China in January 2022; approved to enter clinical trials by FDA
		ROS1	Non-small cell lung cancer	Approved to enter clinical trials by FDA
	HLX-208	BRAF V600E	Solid tumors (metastatic colorectal cancer, non-small cell lung cancer, etc.) LCH and ECD5	Approved to enter Phase 1b/Phase 2 clinical trials by NMPA in January 2022
	FCN-159	MEK	Neurofibromatosis type 1	Global multi-center clinical trial
			Low-grade glioma	
			Malignant melanoma	
			Arteriovenous malformation	Approved to enter clinical trial by NMPA in May 2022
			Histiocytic tumor	Approved to enter clinical trial by NMPA in May 2022
	ORIN1001	-	Solid tumor	Approved Phase 1 clinical trial in the U.S.
	YP01001	VEGFR等	Advanced solid tumor	
	FCN-338	BCL-2	Hematological malignancies	Approved Phase 1 clinical trial in the U.S.
			Relapsed or refractory B-cell lymphoma	Approved to enter Phase 1 clinical trial by NMPA in October 2021
	FH-2001	FGFR/PD-L1	Advanced malignant solid tumors	Approved to enter Phase 1 clinical trial by NMPA in August 2021
	PLK1 Inhibitor	PLK1	KRAS mutations in colorectal and non-small cell lung cancer	
	CHK1 Inhibitor	CHK1	Ovarian cancer and other solid tumors	
	IRAK4/BTK Inhibitor	IRAK4/BTK	DLBCL	

Note 1: last update on 30th October 2022

Innovative R&D - Small Molecule Core Pipeline

Therapeutic Area	Project	Target/MOA	Indication	Pre-Clinical / IND / Phase 1 / Phase 2 / Phase 3 / NDA
Blood System	Avatrombopag Tablet	TPO-R	Chronic idiopathic thrombocytopenic purpura	
	Tenapanor Tablet	NHE 3	End-stage Renal Disease – Hemodialysis	
Metabolism and Digestive System	Ferric Pyrophosphate Citrate	-	Iron replacement for HD patients	
	Tenapanor Tablet	NHE 3	Irritable Bowel Syndrome with Constipation	
	FCN-342	URAT1	Gout	Granted Phase 1 clinical trial by NMPA in November 2021
Infectious Diseases	Molnupiravir	RNA polymerase	Treatment of COVID-19	
	Paxlovid	3CL Protease	Treatment of COVID-19	
	mRNA vaccine BNT162b2	-	Immunization to prevent COVID-19	Administrated in Hong Kong, Macau and Taiwan region
	PA-824	-	XDR – Tuberculosis MDR – Tuberculosis	Launched Pretomanid in the U.S.*
Nervous System	Opicapone Tablet	COMT	Parkinson's syndromes	Launched Ongentys in Europe*
Others	Fortacin spray (Lidocaine Prilocaine spray)	-	Premature ejaculation	Launched in Europe*
	ET-26	-	Anesthesia	Approved to enter Phase 2 clinical trial by NMPA in July 2022
	ORIN1001	-	Idiopathic pulmonary fibrosis	Initiated Phase 1 clinical trial in Chinese Mainland in February 2022; Phase 1 clinical trial in the U.S.
	FCN-016	ROCK	Glaucoma	
	Blood coagulation factor FXLa inhibitor	FXLa	Antithrombotic	
	FH2002	Complement Factor B	IgA nephropathy and other immune abnormalities	

Note: last update on 30th October 2022

Manufacturing - Global Manufacturing System

Wanbang

Henlius

Yao Pharma

Gland

Guilin Pharma
(Antimalarial drug)

Avanc Pharma
(Special formulation)

Sino API Facility

Chongqing API Facility

Henlius +24,000L

Commercial production capacity

- Songjiang Facility Plant (1) received GMP certification , increased commercial production capacity **from 24,000L to 48,000L**
- Songjiang Facility Plant (2) is under construction with designed production capacity of **96,000L**

Global Standard

- Over 10 production lines for API and formulation of Yao Pharma, Wanbang and Guilin Pharma received GMP certification for the U.S., Europe and other markets
- The production line of heparin sodium injection of Wanbang passed the on-site review by the FDA and is qualified to supply the U.S. market
- Gland Pharma received GMP certifications from the U.S., EU, Japan, Australia and other markets

Improved Efficiency: from API to formulation

- Integration of manufacturing facilities to improve efficiency, accelerating the construction of Xuzhou and Chongqing comprehensive facilities and of API facilities in Changsha, Xuzhou and Chongqing

Sublicensed from **MPP** to manufacture **oral COVID-19 drugs from MSD and Pfizer** with world-class manufacturing facilities and to commercialize in agreed low and middle income countries

Small Molecule API **Small Molecule Formulation** **Biopharmaceutical**

Commercialization - Global Commercialization System



Innovative Products Team

- Focusing on Oncology, immunology and Hepatobiliary; building a sales team with around 2,000 people for innovative medicines including Han Li Kang, Han Qu You, Su Ke Xin, Han Si Zhuang and others

Overseas Team

- African commercialization team with 800 frontline sales personnel has developed digital management, user operation and B2B2C service model to provide a one-stop service support system including registration, circulation, academic promotion, post-launch safety alert and other services and has established a solid foundation for registration, marketing and sublicense from MPP
- Collaborated with 5 major wholesalers, 16 group purchasing organizations (GPOs), 21 distributors in the U.S. market. Over 19 collaboration contracts covered 85% of the integrated network distribution system (IDNs)

1H22 Main Progress

- Built a team of more than 200 people for Han Si Zhuang and completed tenders on procurement platforms in 18 provinces
- The largest regional pharmaceutical distribution hub in French-speaking West Africa has been put into operation in Côte d'Ivoire
- Kenya pharmaceutical distribution hub has passed the International Committee of the Red Cross (ICRC) on-site inspection and has become a qualified supplier of ICRC
- Entered into the collaboration and license agreement with Amgen for the exclusive right to commercialize 2 innovative medicines, Otezla® and Parsabiv®. in Chinese Mainland. Leveraging Fosun Pharma's commercialization capabilities to reach patient faster
- Allist granted Fosun Pharma exclusive rights to commercialize Furmonertinib in the broad market (over 1,500 hospitals)
- Entered into the collaboration with Carephar for the exclusive right to commercialize Keverprazan Hydrochloride in Mainland China and for the exclusive rights in other regions or counties as the marketing authorization holder

Med Tech

Med Tech Segment Performance

Segment Revenue



Segment Results



Segment Profit



Medical Devices

Aesthetic Field

- As the core medical aesthetic platform, **Sisram**'s business covers energy based medical aesthetic devices, injectables, home use devices, aesthetic dentistry

Respiratory Care

- Exploiting home/hospital used respiratory devices market through **Breas**

Professional Medical Device & Consumables

- Including Da Vinci surgical robotic system, negative pressure ambulances and other professional medical device

ThermoLift Skin Tightening

Z1 CPAP Machines

Da Vinci Surgical System

Negative Pressure Ambulance



Portable CT BodyTom®

Fosun Diagnosis

- Providing comprehensive solutions including immuno diagnosis, biochemical diagnosis, microbiological diagnosis, molecular diagnosis, POCT, ICL, etc
- Actively integrating the operation and continuously improving R&D and manufacturing capabilities of diagnostic instruments

F-C800p Automatic Biochemical Analyzer

F-i3000 Automated Chemiluminescence Immunoassay Analyzer

COVID-19 RT-PCR Detection Kit

COVID-19 Rapid Antigen Test

Note: Revenue from Med Tech increased by 66.24%YoY, segment result increased by 52.25% YoY, segment profit increased by 19.97% YoY, excluding the impact from equity transfer of Yaneng Bioscience

Medical Devices – Sisram Medical

Establishing **global Wellness Ecosystem** based on energy-based devices business and extending to injectables, aesthetic dentistry and personal care

1H22 Main Progress

- **3 New Launches**: 1) an Ultrasound-based system Alma Ted™ to prevent hair loss; 2) CBD+Professional Skincare Solution™ , which combines the scientific benefits of full-spectrum CBD, shown to visibly reduce redness and calm the appearance of stressed skin; 3) home use device LMNT one
- Strengthened global direct sales teams and built a new UK direct sales team. Direct sales revenue accounts for 64.8% of the total revenue in 1H22, compared to 59.7% in 1H21

Financial Performance



1H22 New Launches

Alma Ted

LMNT one

CBD+Professional Skincare Solution

Alma – Energy-based Devices

The world's leading supplier of energy-based aesthetic medical devices

Launched innovative products including Soprano, ThermoLift Harmony, BeautiFill by LipoLife etc

LMNT. – Personal Care

New brand for personal care

New brand LMNT for home use devices

Launched the first home use device LMNT one

Injectables

Expansion through collaboration

- The hyaluronic acid moisturizing product Profhilo and the first long lasting DaxibotulinumtoxinA product RT002 are both under clinical trial in Chinese Mainland
- Invested in new technologies including silk fibroin-sodium hyaluronate products, fat removal product JS-001 etc.

copulla / FOSHION – Aesthetic Dentistry

- Integrated Fosun resources with the acquisition of Foshion (the dental brand) in July 2021
- Building the new global digital dentistry brand, copulla

Note: sublicense of RT002 is subject to approval of the Independent Shareholders

Medical Devices - Intuitive Fosun

Localization Process

2017 Announced to form a JV with Intuitive Surgical in China in 2016 based on the long-term partnership and **established Intuitive Fosun in Shanghai in 2017**

2019 Marketing the 4th generation Da Vinci XI Surgical System

2020 Da Vinci Surgical System test drives in more than 10 cities across China, with more than 800 doctors from nearly 200 hospitals participating in the experience

2021 **Da Vinci Innovation Center** opened with 1,700 m^2 of space to provide high-quality hands-on precision medicine training to approximately 4,000 doctors per year

2022 Building da Vinci Surgical **Manufacturing R&D Center** in Shanghai, covering about 31.2 acres

Future Localization in technology, manufacturing and services

Made in China
Joint R&D
Global Commercialization

Main Products

Da Vinci Surgical System

- **24** da Vinci Surgical Systems were installed in China in 1H22. As of June 30th 2022, **nearly 300 Systems** were installed in Chinese Mainland, Hong Kong and Macau and completed more than 250,000 surgeries
- As of June 30th 2022, **7,135 systems** were installed worldwide, with more than 55,000 doctors trained to use the system, and **performed over 10 million surgeries**.

Ion Endoluminal System

- The robotic-assisted bronchoscopy platform, Ion, was **approved by FDA in 2019**
- The Ion guided lung nodule biopsy clinical feasibility trial completed enrollment at Shanghai Chest Hospital in October 2021. It is **the first clinical trial using Ion outside the United States**

Medical Diagnosis - Core Product

	Biochemical	Immunodiagnostic	Molecule + Respiratory	Microbiology & Tuberculosis	POCT Chronic Diseases	POCT Acute Infections	Early Tumor Screening
Instrument	 F-C800  F-C800p  XPT	 	F-i1000  SLAN Amplifier  Molecule POCT F-i3000  Extractor	 Rapid Fluorescence  TB ES-15	 GU-2  MLA  GULP	 COVID-19 Rapid Antigen Test	
Reagent & Services	77 Routine Biochemical Reagents 5MyCare (Spiritual)	Tumor Markers15, Thyroid Function8, Gastric Function3, Infection3, Carbohydrate Metabolism2, Sexhormone8	12 Routine PCR COVID-19 RT-PCR Detection Kit Universal Extraction Reagent Monkeypox PCR Detection Kit	NG-Test Disk Susceptibility Test for Fungal/Bacteria Tuberculosis I-SPOT	Blood Glucose Uric Acid (Aq) Blood Lipid	COVID-19 Rapid Antigen Test	G-TEST

In-House Development Collaboration Services

Medical Diagnosis 1H22 Major Progress

- Promoting the integration of medical diagnosis segment to continuously improve the R&D and manufacturing capabilities of diagnostic instruments
- F-C800p Automatic Biochemical Analyzer launched in June 2022, together with the F-i3000 Automated Chemiluminescence Immunoassay Analyzer, formed Fosun Diagnostics biochemical immunoassay pipeline to meet the clinical diagnostic testing needs
- Self-developed COVID-19 Rapid Antigen Test was approved by NMPA in April 2022. It has received EU CE certification and FDA EUA, been included in the EU Common list of COVID-19 antigen tests and completed BfArM registration in Germany
- Self-developed Monkeypox PCR Detection Kit received EU CE certification in May 2022

Healthcare Service

Healthcare Service Segment Performance

Segment Revenue

(RMB million)



Segment Results

(RMB million)



Segment Profit

(RMB million)



Investment 2011-2017

- Built on-site healthcare network
- Gained experience in high-end healthcare
- Launched online healthcare services
- Developed regional medical centers

Operation 2018-2020

- Created advantageous specialty areas
- Online and on-site strategic synergy
- Developed high-end aesthetic medical business
- Constructing specialties for health and wellness

Strategic Upgrade 2021 and beyond

- Integrating resources to build Internet healthcare ecosystem
- Consolidating the leading position as non-public healthcare provider
- Building intelligent Cloud Healthcare
- Building healthcare ecosystem

Note: the revenue growth was mainly due to the growth of online business and the recovery of revenue from offline hospitals. Segment revenue reached RMB 2,552million, 38.39% YoY, excluding the impact of acquiring Guangzhou Xinshi Hospital

Note: the decrease of segment results and segment profit was mainly due to the increased investment in technology development for online business and increased expense for offline hospitals during the pandemic

Healthcare Services - Offline Services

Highlights

Covered Region

Pearl River Delta, Yangtze River Delta, Beijing-Tianjin-Hebei Area, the Central of China and Sichuan-Chongqing Area

5,732 beds[1] in medical service institutions controlled by the Group by the end of June 2022

Healthcare Resources

3000+ doctors

50+ holding and invested hospitals

Collaborated with

220k+ doctors，**20k+** hospitals

Competitiveness

Foshan Chancheng Hospital received JCI certification and the TOP1 non-public hospital in China for 4 consecutive years[2]

Shenzhen Hengsheng Hospital was granted JVF license

Major Hospitals

Pearl River Delta

Regional flagship hospitals include Foshan Chancheng, Shenzhen Hengsheng, etc.

佛山禅医 Foshan Fosun Chancheng Hospital 佛山复星禅诚医院

JCI国际认证医院 Organization Accredited by Joint Commission International

- Class III General Hospital with **1,200** beds
- Realized revenue of **RMB2,010 million** (+22%), and profit of **RMB158 million** (+16%) in 2021
- Fosun Pharma currently holds 86.47% of the share

深圳恒生医院 SHENZHEN HENGSHENG HOSPITAL

- Class III General Hospital with **600** beds
- Acquired 60% stake of Shenzhen Hengsheng Hospital for RMB909 million in November 2017

广东药科大学附属第三医院 广州新市医院

- Class III General Hospital with **800** beds and over 900 doctors and employees
- Acquired 70% stake of Guangdong Xinshi Hospital in January 2022

Other Strategic Region

宿迁市钟吾医院 SUQIAN ZHONGWU HOSPITAL

宿迁市肿瘤医院 SUQIAN CANCER HOSPITAL

卓尔荟 JOYFUL WAY

安徽济民肿瘤医院 ANHUI JIMIN CANCER HOSPITAL

温州老年病医院 WENZHOU GERIATRIC HOSPITAL

星荣整形外科医院 SHINRONG PLASTIC SURGERY HOSPITAL

湖北省人民医院医联体武汉济和医院 HUBEI GENERAL HOSPITAL MEDICAL CONJOINED WUHAN JIHE HOSPITAL

STAR HOSPITAL 星晨妇儿 上海复星医疗旗下高品质医院 医保定点医院

Note1: Last update in June 2022

Note2: According to Ailibi ranking

Healthcare Services - Online Services

- Domestic regulatory, including the 14th Five-Year-Plan, supports the service model of online and onsite healthcare services. Fosun Health will continuously accelerate digitalization and provide patient with closed loop services
- Integrated online and offline healthcare services from 2021, has **received 8 internet hospital licenses** as for now
- **Building online medical service platform** to provide healthcare services, pharmaceutical and med tech e-commerce , health insurance service and health management services.



GSP + self-operated central warehouse + collaborated distribution

60 cities next-day delivery, the national average is 1-3 days

Collaborated with domestic distributor and pharmacy

O2O delivery in 300 cities with same-day delivery goal

Sinopharm Performance

Revenue



Profit Attributable



Profit Attributable to Fosun Pharma



- Vigorously promoted the operational innovation and technology upgrading of pharmaceutical distribution services, enhance the scalable, professional and tailoring services advantages of pharmaceutical distribution. **1H22 revenue from pharmaceutical distribution was RMB196,523.94 million (+3.19%YoY)** , successfully resisted the pandemic challenge and maintained a relatively stable development trend.
- Utilized national leading network service capability and resource allocation advantages of medical device industry to provide all-round distribution services for various governments authorities and corporate customers. **1H22 revenue from device distribution was RMB53,684.24 million (+12.36%YoY),** and the growth rate continuously surpassed the growth of the pharmaceutical distribution
- Made efforts to speed up the acquisition of qualifications and the introduction of varieties, continuously improved the operation efficiency and strengthened the comprehensive service capability for C-end patients and consumers. **1H22 revenue from the retail pharmacy business was RMB15,274.10 million, (+11.31% YoY)**, and the operating profit margin of retail business (+0.05 percentage point YoY)

Disclaimer and copyright

- 本文件中所包含的所有内容（包括预测性描述），复星医药、陈述人或提供人不保证其完全准确、完整或及时，如因有关内容存在错误、遗漏或失准之处而引致的行为或结果，复星医药、陈述人或提供人对此不承担责任。
- 本文件内容不包含亦不应被视为任何投资建议，投资者基于本文件中内容做出的投资决策，责任自负。
- 本文件及其中所包含内容的所有权利包括版权均由复星医药独家所有，其中相关的“FOSUN”和“复星”字样、图案及相关LOGO标识均为复星医药合法所有的字号、商标和标识。该等资料和内容未经复星医药书面同意，任何第三方不得以包括转载在内的任何方式加以使用。

- Fosun Pharma, the Representor or the Provider will not warrant the accuracy, the completeness and the timeliness of all information and contents, including predictive description, contained in the PPT documents/visual materials. In the event of any mistake, omission, and inaccuracy, Fosun Pharma, the Representor or the Provider should not be held for any liabilities in this regard.
- The PPT documents/visual materials will not include and should not be deemed as any investment proposals. The investor should take their own responsibilities for any determinations so come to based upon the information contained in the PPT documents/visual materials.
- Fosun Pharma is entitled to all rights, including copyright, pertaining to the PPT documents/visual materials. The characters, the designs and other related logos, like “Fosun” and”复星” , are the trade name, trademark and the logos legally owned by Fosun Pharma. Without written consent offered by Fosun Pharma, any third party should not utilize such materials and information in any manner, including reprinting.

FOSUN PHARMA
复星医药
持续创新 乐享健康

复星医药微信公众号
www.fosunpharma.com